Targeting MYC-driven growth and proliferation in prostate cancer

Over the last decade, the oncogene MYC has emerged as a key driver of survival, growth and proliferation in prostate cancer. The transforming activity of this potent oncogene partly depends on its ability to modulate RNA Pol I transcription activity which is required for ribosome synthesis. Considering that cancer cells are dependent on high rates of RNA Pol I transcription, we explored the efficacy of targeting PolI transcription with a small molecule inhibitor in prostate cancer